Ladenburg Thalmann Financial Services’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100	Closed	–	–	5625
2019 Q1	$0	Hold	100	–	–	﹤0.01%	5565
2018 Q4	$0	Buy	+100	New	+$151	﹤0.01%	5576

Ladenburg Thalmann Financial Services's OMED Position: Q2 2019 in Review

Ladenburg Thalmann Financial Services sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 100 shares.

Ladenburg Thalmann Financial Services first reported a position in OMED in Q4 2018 and held it in 2 quarters. The position peaked at $0 in Q1 2019. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.

Ladenburg Thalmann Financial Services reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 100 OncoMed Pharmaceuticals, Inc. shares in Q2 2019.
Ladenburg Thalmann Financial Services first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
Ladenburg Thalmann Financial Services's OncoMed Pharmaceuticals, Inc. position peaked at $0 in Q1 2019.
0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q2 2019, filed 15 Aug 2019.